Comparative Pharmacology
Head-to-head clinical analysis: PENCICLOVIR versus ZOVIRAX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PENCICLOVIR versus ZOVIRAX.
PENCICLOVIR vs ZOVIRAX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Penciclovir is a nucleoside analog that inhibits viral DNA polymerase. It is phosphorylated by viral thymidine kinase to penciclovir triphosphate, which competitively inhibits viral DNA polymerase and terminates DNA chain elongation.
After intracellular phosphorylation to acyclovir triphosphate, selectively inhibits viral DNA polymerase and incorporates into viral DNA, causing chain termination.
Topical: Apply 1% cream every 2 hours while awake (approximately 9 times/day) for 4 days. Oral: 500 mg twice daily for 5 days.
Herpes simplex: 200 mg orally 5 times daily for 10 days; or 400 mg orally 3 times daily for 5-10 days. Herpes zoster: 800 mg orally 5 times daily for 7-10 days. IV: 5-10 mg/kg every 8 hours for immunocompromised patients with HSV/VZV.
None Documented
None Documented
Terminal half-life: 2.0–2.5 hours (healthy adults); prolonged to ~9–10 hours in renal impairment (CrCl <30 mL/min); clinical context: dosing interval adjusted based on renal function.
Terminal elimination half-life is 2.5-3.3 hours in adults with normal renal function; prolonged to 19.5 hours in anuria (creatinine clearance <10 mL/min).
Renal excretion: >70% as unchanged penciclovir via glomerular filtration and tubular secretion.
Renal excretion of unchanged drug via glomerular filtration and tubular secretion accounts for 76-82% of elimination; fecal excretion is less than 2%.
Category A/B
Category C
Antiviral
Antiviral